
Simulations Plus (SLP) Stock Forecast & Price Target
Simulations Plus (SLP) Analyst Ratings
Bulls say
Simulations Plus Inc. demonstrated a robust performance in Q3, with the dollar value of awarded work not yet recognized increasing by approximately 30% year-over-year, indicating strong demand for its services. The software segment, which generates the majority of the company's revenue, achieved a notable 22% year-over-year increase in revenue, correlated with a positive shift in biotech funding and proposal activity from clients. This momentum is further supported by improved RFP flow and confidence among global biopharmaceutical clients, suggesting a favorable outlook for the company’s growth trajectory in the pharmaceutical research and education market.
Bears say
Simulations Plus Inc. reported a -6% year-over-year decline in total revenue for F4Q:25, despite showing a +13% increase for the full-year, indicating volatility and inconsistency in revenue generation. The company's guidance for F1Q:26 suggests an anticipated further decline of -3% to -5%, and its projected revenue growth of only +0-4% for F26 appears underwhelming compared to peers in the pharmaceutical technology and health-tech sectors. Additionally, the decrease in revenue from key segments, including a notable loss of a large client in the CDMO business, raises concerns about the company's long-term growth trajectory and market competitiveness.
This aggregate rating is based on analysts' research of Simulations Plus and is not a guaranteed prediction by Public.com or investment advice.
Simulations Plus (SLP) Analyst Forecast & Price Prediction
Start investing in Simulations Plus (SLP)
Order type
Buy in
Order amount
Est. shares
0 shares